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The twin-arginine protein translocation (Tat) system mediates trans-
port of folded proteins across the cytoplasmic membrane of bacteria
and the thylakoid membrane of chloroplasts. The Tat system of
Escherichia coli is made up of TatA, TatB, and TatC components. TatBC
comprise the substrate receptor complex, and active Tat translocases
are formed by the substrate-induced association of TatA oligomers
with this receptor. Proteins are targeted to TatBC by signal peptides
containing an essential pair of arginine residues. We isolated substi-
tutions, locating to the transmembrane helix of TatB that restored
transport activity to Tat signal peptides with inactivating twin argi-
nine substitutions. A subset of these variants also suppressed inacti-
vating substitutions in the signal peptide binding site on TatC. The
suppressors did not function by restoring detectable signal peptide
binding to the TatBC complex. Instead, site-specific cross-linking ex-
periments indicate that the suppressor substitutions induce confor-
mational change in the complex and movement of the TatB subunit.
The TatB F13Y substitution was associated with the strongest sup-
pressing activity, even allowing transport of a Tat substrate lacking a
signal peptide. In vivo analysis using a TatA–YFP fusion showed that
the TatB F13Y substitution resulted in signal peptide-independent
assembly of the Tat translocase. We conclude that Tat signal peptides
play roles in substrate targeting and in triggering assembly of the
active translocase.
protein transport | twin arginine signal peptide | Tat pathway |
genetic suppressor
Alarge proportion of prokaryotic proteins are trafficked intoor across the cytoplasmic membrane. Extracytoplasmic
proteins are synthesized with cleavable N-terminal signal pep-
tides to address them to export machineries located in the cy-
toplasmic membrane. Signal peptides are generally between 20
and 30 amino acids in length and have a recognizable tripartite
structure comprising a basic n-region, a hydrophobic h-region,
and a polar c-region with a signal peptidase cleavage site.
The Sec pathway is the major route of protein export in most
prokaryotes, transporting unfolded polypeptides across the cyto-
plasmic membrane. In bacteria it is comprised of a SecYEG channel
complex and a peripheral membrane ATPase, SecA (see refs. 1 and
2 for recent reviews). The initial discovery of Sec components was
driven by genetic approaches using Escherichia coli to isolate sup-
pressors of defective Sec substrate proteins and inactive signal pep-
tides (3, 4). These genetic suppressors also contributed significantly
to mechanistic understanding of Sec-dependent protein trans-
location (5–7). More recently, it has been shown that Sec signal
peptides have dual roles: they serve to target their passenger proteins
to the Sec machinery (3, 8) but also to allosterically activate the SecY
channel (9).
The twin-arginine protein translocation (Tat) pathway oper-
ates in parallel to the Sec pathway to transport folded proteins
across the prokaryotic cytoplasmic membrane and the thylakoid
membrane of plant chloroplasts (10, 11). Proteins are targeted to
the Tat pathway by N-terminal signal peptides that contain a
conserved twin arginine motif at the n-region/h-region boundary
(12, 13) (Fig. 1A). The Tat system in the model bacterium E. coli
requires three membrane-bound subunits: TatA, TatB, and TatC
(14–17). The TatB and TatC proteins form a multivalent com-
plex that binds Tat substrates through their twin arginine signal
peptides (18–20). Numerous experiments have shown that the
TatC component recognizes the twin arginine motif (21–26),
whereas TatB is close to the signal peptide h-region (27, 28).
Signal peptides have been shown to penetrate deeply into the
TatBC complex (29) and, in thylakoids at least, this deep-binding
mode may be modulated by the transmembrane proton elec-
trochemical gradient (PMF) (30).
It is generally accepted that the TatA protein forms the protein-
conducting element of the Tat pathway. TatA oligomers assemble
at the substrate-bound TatBC complex, dependent on the PMF
(27, 31–35). Current models for Tat transport propose that TatA
oligomers either provide form-fitting channels of varying diameter
that adapt to the size of the folded passenger domain, or that
oligomeric assemblies of TatA cause a localized weakening of the
membrane and transient bilayer disruption accompanied by sub-
strate transport (reviewed in refs. 10 and 11). An implicit pre-
diction of the latter model is that transient membrane rupture
would be expected to be accompanied by ion leakage.
In this study we have addressed the function of the twin-
arginine signal peptide in the Tat transport process by isolating
genetic suppressors that either restore transport to signal pep-
tides harboring transport inactivating twin arginine substitutions,
or that restore Tat activity to a TatC variant that has an inactive
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signal peptide binding site. Our results identified a common set
of substitutions, primarily located in the transmembrane helix of
TatB that can suppress both types of transport defect. Bio-
chemical analysis of Tat translocases harboring these substitu-
tions indicates that at least one of them, TatB F13Y, promotes
signal peptide-independent TatA assembly. Our findings show
that, like Sec signal peptides, Tat targeting sequences have two
separable roles in the transport process.
Results
Single Amino Acid Substitutions in TatB Permit Export of Twin-
Arginine Substituted Signal Peptides. Previous genetic screens us-
ing maltose binding protein (21, 22) or GFP (23) fused to the Tat
signal sequence of E. coli TorA identified mutations that were
able to restore some level of Tat transport to fusions with export-
defective twin arginine substitutions. These substitutions were
located toward the N-terminal end of the TatB transmembrane
helix or within the cytoplasmic loops of TatC. To shed light on
potential functions of signal peptides during Tat transport, we
initiated an independent genetic screen using a native E. coli Tat
substrate, AmiA, as our reporter. AmiA is an N-acetylmuramoyl-
L-alanine amidase that remodels the cell wall during growth. In
the absence of a functional Tat system, the cell envelope is im-
paired because of the inability to correctly localize AmiA and the
related Tat substrate AmiC, rendering E. coli sensitive to killing
by SDS (36). Using a strain lacking chromosomal tat genes and
amiA/amiC (37), coproduction of plasmid-encoded AmiA (from
the medium copy construct pSUAmiA) (36) alongside a separate
plasmid, pTAT1d (producing TatABC from a compatible me-
dium copy plasmid) (38), permits the strain to grow on LB me-
dium containing 2% (wt/vol) SDS (SI Appendix, Fig. S1). We
then mutated the consecutive arginines in the Tat signal peptide
of plasmid-encoded AmiA to each of the amino acid pairs RD,
RE, RH, RN, RQ, KH, KQ, or HH. As expected, each of these
substitutions abolished growth on SDS (SI Appendix, Fig. S1).
Next we screened a tatBmutant library, generated in pTAT1d by
error-prone PCR, for clones that supported growth of strains car-
rying AmiA with variant signal peptides (38). Each AmiA twin
arginine variant was challenged with this library, screening ∼10,000
clones for each construct. In total across the screening campaign
we isolated 30 individual clones. Upon rescreening, 20 of the clones
retained the ability to suppress the inactive signal peptide variant of
AmiA against which they were originally isolated. These clones are
listed in SI Appendix, Table S1. Substitutions appeared to cluster
within the transmembrane region of TatB, including L9Q that
appeared in seven of the clones and F13Y that occurred in five
clones, whereas F6Y, E8K, L9P, and L10P were each found once.
It should be noted that E8K, L9P, and L9Q substitutions have
previously been identified as suppressors of inactive signal peptides
(21, 22). We also found clones, each isolated twice, which con-
tained no substitutions in the transmembrane domain, where the
first substitution was in the amphipathic helix of TatB (clones
BRQ1, BRQ2, BRQ3, and BRQ5).
We introduced the individual amino acid substitutions F6Y,
E8K, L9P, L9Q, L10P, F13Y, K30I, and I36N into TatB encoded
within the tatABC operon on the very low copy number plasmid
pTAT101 (39) and tested their ability to support export of wild-
type AmiA and to suppress each of the RD, RE, RH, RN, RQ,
KH, KQ, or HH AmiA signal sequence variants (Fig. 1 B and C,
Table 1, and SI Appendix, Fig. S2). Each of the substitutions was
able to support transport of wild-type AmiA, but they varied in
their ability to permit export of the AmiA signal sequence vari-
ants. For example, the F13Y variant of TatB supported growth
on SDS for all of the signal peptide variants tested, whereas the
L9Q, L10P, K30I, and I36N TatB substitutions could suppress
some of the signal sequence variants, but not KH, KQ, and HH
substitutions. To determine whether the suppression observed
was specific for the AmiA signal peptide, we generated an ad-
ditional construct where the signal peptide of the Tat substrate
SufI was fused to the mature portion of AmiA and the same twin
arginine substitutions were introduced (Table 1 and SI Appendix,
Fig. S3). The TatB variants generally showed the same pattern of
suppression of SufI signal peptide substitutions, although the
TatBL10P, K30I, and I36N variants could not suppress RD or
RE substitutions in the SufI signal peptide.
A Subset of TatB Signal Peptide Suppressors also Suppress TatC
Signal Peptide Binding Site Mutants. In a complementary ap-
proach, we asked whether it was possible to select suppressors of
defects in the signal peptide binding site on TatC. Residue F94 in
E. coli TatC is highly conserved and lies within the signal peptide
binding site (25, 40) (Fig. 2A), and substitution to other amino acids
is poorly tolerated (41). We constructed substitutions of F94 to each
of the small neutral amino acids Ala and Gly, helix-breaking Pro,
polar residues Ser and Gln, positively charged Arg and Lys, and
negatively charged Asp. These substitutions were introduced into
TatC encoded on both the medium copy plasmid pTAT1d and the
very low copy plasmid pTAT101 that also carry wild-type tatA and
tatB. SI Appendix, Fig. S4 shows that substitutions to Asp, Gln, or Pro
resulted in a complete inability of strain DADE (ΔtatABCD, ΔtatE)
(42) to grow in the presence of SDS at both medium and very low
copy number. We selected the F94Q substitution of TatC and
constructed three mutant libraries in the pTAT1d vector by error-
prone PCR in an attempt to identify suppressors of this inactivating
tatCmutation. LibC1 carried mutations in the first 93 codons of tatC,
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Fig. 1. Isolation of signal sequence suppressors in tatB. (A) Schematic rep-
resentation of a twin arginine signal peptide. The signal peptide sequences
of E. coli Tat substrates SufI and AmiA are given underneath, with residues
matching the Tat consensus motif in red, the consecutive arginines in red
underline, and the signal peptidase cleavage site in black underline. (B and C)
An example of screening results. Growth of MCDSSAC ΔtatABC coproducing
the indicated TatB variants (with wild-type tatA and tatC) from pTAT101,
alongside (B) the HH or (C) RE-substituted signal peptide variants of AmiA, on
LB agar supplemented with chloramphenicol and kanamycin, with or without
the addition of 2% (wt/vol) SDS as indicated. An 8-μL aliquot of each strain/
plasmid combination following aerobic growth to an OD600 of 1.0 was spotted
and incubated for 16 h at 37 °C.
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LibC2 carried mutations in tatC from residue 95 onwards, and
LibAB contained mutations in the tatA and tatB genes.
A number of suppressors were identified from screening the
LibC1 and LibC2 libraries for growth on SDS plates. However,
sequence analysis indicated that for each of these Tat active
mutants there was substitution at the tatC F94Q codon to tatC
F94Y, W or L codons. In contrast, after screening more than
180,000 clones from the LibAB library, 11 mutants were isolated
that were able to rescue the growth defect of TatC F94Q on SDS
plates, of which 5 were still able to support growth on SDS following
fresh transformation of strain DADE with the isolated plasmid.
These clones are listed in SI Appendix, Table S2. Interestingly, each
of these suppressors encoded either TatB L10P, F13Y, or I36N,
which had been identified in our prior screen for signal sequence
suppressors. Introduction of each of these substitutions, individually,
into the very low copy number pTAT101CF94Q plasmid supported
growth of strain DADE on SDS-containing media (Fig. 2B), in-
dicating that these TatB variants are each able to rescue the Tat-
inactivating F94Q TatC substitution.
Because these three TatB substitutions that suppress the TatC
F94Q defect were previously isolated as suppressors of inactive
Tat signal sequences, we asked whether any of the other tatB
signal sequence suppressors we had found could also rescue the
TatC F94Q substitution. Fig. 2C shows that in addition to L10P,
F13Y, and I36N, L9Q could restore Tat activity to cells pro-
ducing TatC F94Q. The location of each these residues on a
model of TatB is shown in Fig. 2D. We next asked the question
whether any of these TatC F94Q suppressors could restore Tat
activity to other inactivating substitutions in TatC. Fig. 2E shows
that two different inactivating substitutions of E103 in the signal
peptide binding site, either E103A or E103K (25, 40, 41) (Fig.
2A), could also be complemented by three of the four suppres-
sors of tatCF94Q (I36N did not suppress these substitutions), but
they could not restore Tat activity caused by inactivating TatC
substitutions located outside the signal peptide binding site (SI
Appendix, Fig. S5). Finally, we tested whether F94Q-suppressing
substitutions were additive (i.e., whether when combined they
resulted in a stronger suppressing activity). However, SI Appen-
dix, Fig. S6A shows that none of the pairwise combinations we
tested gave any suppression of tatCF94Q and, with the exception
of the F13Y, I36N substitution that showed some suppression of
the RN signal peptide variant, the combined suppressors lost
suppressive function of RN or KK substitutions of the SufI signal
peptide (SI Appendix, Fig. S6B). We therefore conclude that the
suppressor mutations, when combined, have detrimental rather
than additive effects on suppression activity.
The TatB F13Y and L9Q Substitutions Support Export of AmiA Lacking
a Signal Peptide. The results above indicate that the TatBF13Y
substitution is the strongest suppressor of inactive Tat signal
peptides, allowing the E. coli Tat system to recognize all eight of
the different twin arginine motif substitutions tested, as well
as suppressing the TatC F94Q mutation. We therefore tested
whether more severe signal peptide defects could be suppressed
by this TatB variant. Fig. 2F shows that, remarkably, even after
truncation of the signal peptide by removal of the h-region, or
indeed complete removal of the entire signal peptide-coding
sequence of AmiA, we could still detect some Tat-dependent
translocation of the AmiA passenger domain in the presence of
TatBF13Y. The TatB L9Q substitution, which was the strongest
suppressor of signal peptide defects after F13Y, also supported
some translocation of mature AmiA; however, we were not able
to detect export of mature AmiC in the presence of either of
these two suppressor substitutions (SI Appendix, Fig. S6C). We
conclude that TatB L9Q and F13Y allow at least one Tat sub-
strate to be transported independently of any signal peptide.
Variant TatB Proteins Support Good Transport Activity of a Native Tat
Substrate but Much Poorer Transport When the Signal Peptide Is
Altered. We next addressed whether the TatB substitutions
were detrimental to the activity of the Tat system. Using over-
produced His-tagged, but otherwise native SufI as a substrate, it
was seen that mature SufI was clearly detected in the periplasmic
fractions of all of the strains tested, although TatBI36N seemed
to support only low levels of transport (SI Appendix, Fig. S7A).
However, we were unable to detect transport of the RD, RN, or
KQ signal peptide variants of SufI in the presence of TatBF13Y
(SI Appendix, Fig. S7B) or of a twin-lysine substituted His-tagged
CueO in the presence of TatBE8K or F13Y (Fig. 3). It therefore
appears that there is very low export efficiency of substrates with
variant signal peptides in the suppressor mutant strains.
The TatB Suppressors Do Not Restore Biochemically Detectable Signal
Peptide Binding to TatBC. We subsequently sought to understand
the biochemical basis for the action of the TatB suppressors. Our
initial hypothesis was that they acted to increase the affinity of the
TatBC complex for the variant signal peptides, or to restore
binding to complexes containing the TatC F94Q or E103A/E103K
substitutions. First we produced His-tagged GFP with variants of
the SufI signal peptide at its N terminus and assessed how much
TatBC could be copurified with this from detergent-solubilized
membrane fractions. Fig. 4A shows that when the wild-type signal
peptide was fused to GFP, wild-type TatBC or variants harboring
the TatB E8K, F13Y, or I36N substitutions were coeluted with
His-tagged SufI-GFP. However, no TatBC was detected when the
RR motif in the signal peptide was mutated to RD, RN, or KK,
even in the presence of the TatB suppressor substitutions (despite
the fact TatBC and GFP were clearly present in all of the input
samples) (SI Appendix, Fig. S8 A and B). Very similar behavior
was also seen when His-tagged AmiA variants were used as sub-
strate for copurification experiments (SI Appendix, Fig. S9). Thus,
TatBC and TatBF13YTatC copurified with the His-tagged wild-
type AmiA precursor, but no TatBC was detected when RD, RN,
KK, or KQ substitutions were introduced into the signal peptide,
or when the AmiA signal peptide was lacking. We conclude that
the TatB suppressors do not detectably restore binding of variant
Table 1. Summary of the results obtained from TatB suppressor
analysis against the indicated twin-arginine substitutions in the
AmiA and SufI signal peptides
N indicates no export; Y indicates export. Gray shading indicates suppres-
sion of the equivalent substitutions in both signal peptides.
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signal peptides to the TatBC complex. Because several TatB
variants can support transport of substrates with defective signal
peptides, but not without signal peptides (Fig. 3), we infer that the
defective signal peptides must still weakly interact with the TatBC
complex at a level that is not detected by our copurification assay.
We then tested whether any of the four suppressors, TatB
L9Q, L10P, F13Y, and I36N, which allow Tat transport in the
presence of the TatC F94Q and E103K mutations, acted to re-
store substrate binding to TatBC complexes containing these
signal sequence binding-site substitutions. Although high GFP
fluorescence and strong TatBC signals were detected in whole
cells (SI Appendix, Fig. S8 C and D), only wild-type TatBC was
found to copurify with His-tagged SufIss-GFP (Fig. 4B). Thus,
as expected, TatC substitutions F94Q or E103K prevented
copurification of the TatBC-substrate complex, consistent with
loss of signal peptide binding detected for substitutions at these
amino acid positions (25, 40). However, detectable signal peptide
binding was not restored by introduction of the individual TatB
suppressor substitutions. We conclude that the TatB suppressors
do not act by rescuing signal peptide binding.
The TatBC Complexes Harboring TatB Suppressor Substitutions Are
Conformationally Altered. We next investigated whether TatBC
complexes could still be detected when any of the TatB L9Q, L10P,
F13Y, or I36N substitutions were present in TatB. Membranes
harboring wild-type TatA and TatC along with each of these TatB
variants were solubilized with digitonin and analyzed by blue na-
tive-gel electrophoresis (BN-PAGE). As shown in Fig. 5A, the
wild-type TatBC complex solubilized with digitonin migrated close
to the 440-kDa marker, as reported previously (e.g., ref. 43). The
TatB L9Q, F13Y, and I36N variants were also associated with a
complex of apparently identical size to wild-type TatBC, whereas
for membranes producing TatB L10P, very little TatBC complex
could be detected, even though both proteins were solubilized from
the membrane (SI Appendix, Fig. S10). Interestingly, the L9Q and
F13Y TatB substitutions also resulted in the appearance of a
second band of apparently higher mass that was absent from the
sample containing wild-type TatBC (Fig. 5 A and B).
We wondered whether this additional band might arise because
of the presence of excess TatA bound to the variant complexes.
However, blotting the BN gels for TatA showed the distinct
TatA-laddering pattern reported previously (44, 45) was detect-
able for all of the samples, but there was no obvious TatA cross-
reactive material migrating at the same position as the higher mass
W S P
WT E8K F13Y
DnaK
pre-CueO-his
DnaK
pre-CueOkk-his
W S P W S P
97
66
mat-CueO-his
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66
Fig. 3. TatB suppressors support export of a Tat substrate with its native
signal peptide. E. coli strains producing native levels of TatA, TatC, and the
indicated TatB variants, and overproducing His-tagged CueO with a wild-
type (Upper) or KK-substituted (Lower) signal peptide were fractionated
into whole cell (W), spheroplast (S), and periplasm (P) fractions. Equivalent
amounts of each fraction were separated by SDS/PAGE and analyzed by
Western blot with antibodies against CueO and the cytosolic marker DnaK.
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Fig. 2. Isolation of suppressors of the TatC F94Q inactivating substitution. (A) Model of E. coli TatC (from ref. 47) showing the location of the F94 and E103
residues (in red) that form part of the signal peptide binding site. (B, C, and E) Growth of DADE (ΔtatABCD, ΔtatE) coproducing wild-type TatA alongside; (B
and C) F94Q-substituted TatC or (E) E103A-substituted TatC, and the indicated substitution in TatB from plasmid pTAT101 on LB agar or LB agar containing
2% (wt/vol) SDS. (D) Structure of E. coli TatB (from ref. 68) with the locations of the TatCF94Q suppressor substitutions shown in red. (F) Strain MC4100 ΔamiA
ΔamiC ΔtatABC coproducing the indicated TatB variants (with wild-type tatA and tatC) from pTAT101, alongside either a signal peptide variant of SufI
lacking the h-region fused to the AmiA mature domain (SufIssnoH-AmiA), or the mature AmiA domain alone (mAmiA) on LB agar or LB agar containing 1%
SDS. For all growth tests, a single colony of each strain/plasmid combination was resuspended in 30 μL of PBS and an 8 μL aliquot was spotted onto LB agar
supplemented with appropriate antibiotics, along with SDS as indicated and incubated for 16 h at 37 °C.
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TatBC-containing complex (Fig. 5B). To examine whether the
presence of TatA was required for these higher molecular weight
variant TatBC complexes to form, we repeated the BN-PAGE
analysis in the absence of TatA (or its paralog TatE) (16). Surpris-
ingly, this resulted in the apparent aggregation of the variant TatBC
complexes, yielding a series of bands of apparent masses well above
440 kDa that were not seen for the wild-type (Fig. 5C). We infer from
this finding that there is a conformational alteration in the TatBC
complex induced by the presence of the L9Q or F13Y TatB substi-
tutions that in the absence of TatA causes further oligomerization.
Conformational alterations in the TatBC complex have been
previously detected by disulfide cross-linking (46, 47). Cléon et al.
(47) reported that when a Tat substrate was overproduced, a
disulfide cross-link between M205C in transmembrane helix 5 of
neighboring TatC proteins could be detected in vivo, suggesting
the formation of a transient TatC dimer in response to substrate
binding. Fig. 5D confirms that dimerization through TatC M205C
is not observed unless cells also harbor an overproduced Tat
substrate, in this case CueO. The TatC M205C dimer induced by
CueO is almost completely absent when the F94Q substitution is
introduced into TatC, again supporting the conclusion that sub-
strate binding promotes TatC dimerization (Fig. 5D). Interest-
ingly, however, when either the TatB L10P or F13Y substitutions
were present, a TatC M205C cross-link was detected in the ab-
sence of overexpressed substrate. We wondered whether these
TatB substitutions rendered the TatBC complex more responsive
to the presence of endogenous substrates. To test this, we also
introduced the signal peptide binding-defective F94Q substitution
into TatC M205C. However, as Fig. 5D shows, the TatC M205C
dimer can still be detected in the presence of TatB L10P or F13Y
substitutions, even when the F94Q-inactivating substitution is
present, and is therefore independent of signal peptide binding.
We conclude that at least a subset of the TatB suppressors induces
conformational changes in the TatBC complex, and that the TatB
L10P and F13Y substitutions potentially mimic the substrate-
bound form of the complex.
The TatB F13Y Substitution Promotes Signal Peptide-Independent
Oligomerization of TatA in Vivo. Substrate binding to the TatBC
complex is a prerequisite for the assembly of a TatA oligomer.
TatA oligomer assembly in vivo can be followed by fluorescence
microscopy in cells producing a chromosomally encoded TatA–
YFP fusion protein (34). When Tat substrates are present at
native level, TatA oligomers are found with low frequency, but
this frequency can be significantly increased by overproduction
of a Tat substrate protein with a functional signal peptide (34,
35). This finding is confirmed in Fig. 6A, where clusters of TatA–
YFP can be seen in cells overproducing AmiA from a plasmid.
As expected, introduction of the F94Q codon substitution into
chromosomally encoded tatC prevented the AmiA-induced
clustering of TatA–YFP, resulting in a halo of delocalized TatA
around the cell periphery (Fig. 6A), consistent with the inability
of the TatC variant to bind substrates. We next assessed whether
any of the TatC F94Q suppressors, TatB L9Q, L10P, F13Y, or
I36N (introduced into chromosomal tatB) affected the oligo-
merization of TatA–YFP (Fig. 6B and SI Appendix, Fig. S11).
Remarkably, we found that the presence of the TatB F13Y
substitution promoted constitutive assembly of TatA–YFP in the
absence of overproduced Tat substrates (Fig. 6B), and the TatA–
YFP assemblies persisted even in the presence of the TatC F94Q
substitution for this variant (but not for L9Q, L10P, or I36N) (SI
Appendix, Fig. S11). Taken together, these results indicate that
the TatB F13Y substitution triggers signal peptide-independent
assembly of TatA oligomers.
No Leak Across the Cytoplasmic Membrane When Cells Produce the
Tat System Containing TatB F13Y. One of the current models for
Tat transport posits that TatA oligomers facilitate transport of
substrates by causing a localized weakening of the bilayer and
transient disruption (discussed in refs. 10 and 11). Such a
mechanism might be expected to be accompanied by increased
permeability of small molecules associated with assembled TatA.
The availability of a TatB variant (F13Y) that causes TatA to
accumulate in the assembled state provides an experimental tool
to investigate this issue.
First, we asked whether overexpression of Tat systems con-
taining the TatB suppressors L9Q, L10P, F13Y, or I36N from an
arabinose-inducible promoter had any effect on the growth rate of
E. coli. Fig. 7A shows that when production of each of these
variant Tat systems was induced by the addition of arabinose, cells
grew more slowly than when the wild-type Tat system was over-
expressed, with the TatBL9Q substitution having a particularly
detrimental effect on growth rate. This finding indicates that some
level of toxicity is associated with overproduction of these variants.
We next assessed whether the TatB variants facilitated membrane
permeability using an osmotic lysis method previously used to
monitor solute movement through the Sec protein transport
channel (48). Here, spheroplasts containing wild-type or variant
Tat translocases were diluted into an iso-osmotic solution of the
uncharged sugar xylitol and permeation of xylitol into the cells was
assessed by monitoring turbidity associated with osmotically in-
duced spheroplast lysis. Spheroplasts expressing a SecY variant
that is known to increase permeability (48, 49) rapidly lysed fol-
lowing dilution into xylitol solution (Fig. 7B). However, no lysis
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Fig. 4. The TatB suppressors do not restore signal peptide binding to the
TatBC complex. (A) C-terminally His-tagged GFP with the wild-type (RR) or
twin-arginine substituted SufI signal peptide at its N terminus, as indicated,
was purified by magnetic nickel beads from digitonin-treated cell extracts
coexpressing TatC along with either wild-type TatB or the E8K, F13Y, or I36N
substituted variants. (B) C-terminally His-tagged GFP with the wild-type SufI
signal peptide at its N terminus was purified by magnetic nickel beads from
digitonin-treated cell extracts coexpressing TatB and TatC with the indicated
amino acid substitutions. For both panels the elution fractions from each
sample were normalized for GFP fluorescence and an equivalent amount of
purified SufIss-GFP-His was loaded onto SDS/PAGE (4–15% Mini-PROTEAN
TGX precast gradient gel) followed by Western blot using TatB and TatC
mixed antibodies.
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was observed for spheroplasts producing any of the variant Tat
translocases, even those harboring the TatA-oligomerizing TatB
F13Y variant (Fig. 7B). Western blotting confirmed that the Tat
proteins were present in these membranes (Fig. 7C). These results
show the TatA assemblies induced by the TatB F13Y substitution
do not result in a small molecule leak across the cytoplasmic
membrane.
Discussion
In this work, a genetic approach has been taken to shed light on
functions of twin arginine signal peptides during Tat transport.
Two complementary screens, the first to identify substitutions in
TatB permitting export of substrates with inactivating substitu-
tions at the signal peptide arginine pair, and the second to
identify rescue mutations of the TatC signal peptide binding site,
converged on a similar group of tatB suppressors. Four TatB
substitutions were identified: three in the transmembrane do-
main, L9Q, L10P, and F13Y, and one in the amphipathic helix
(I36N) that restored Tat transport in the presence of the inac-
tivating TatC F94Q substitution. The same three substitutions in
the transmembrane helix could suppress inactivating substitu-
tions at E103, and also in the signal peptide binding site. Of these
three, the F13Y substitution displayed the strongest suppressing
activity, allowing export all of the twin arginine substitutions
tested, and even allowing some translocation of AmiA com-
pletely devoid of a signal sequence.
A combined bioinformatics and mutagenesis approach has
shown the TatB transmembrane helix to bind along trans-
membrane helix 5 of TatC (50), and this is consistent with in
vitro disulfide cross-linking studies (25, 39). Signal peptide
binding to the TatBC complex is suggested to cause movement of
TatB from its resting-state binding site on TatC to a site else-
where on the protein. This is proposed to prime TatA to occupy
the same binding site, which in turn triggers assembly of further
TatA molecules to form the active translocase (50) (Fig. 8). After
our biochemical experiments revealed that the suppressors did
not function by restoring detectable binding of signal peptides to
the TatBC complex (Fig. 4 and SI Appendix, Fig. S9), we con-
sidered whether the TatB substitutions were mimicking the
substrate-driven conformational changes that prime the trans-
locase for TatA recruitment, but in the absence of substrate
binding. Our analysis using BN-PAGE showed that the TatB
L9Q, L10P, and F13Y substitutions caused conformational al-
terations in the resting TatBC complex (Fig. 5 A and B). The
complex containing the L10P substitution appeared more labile
because very little full-sized TatBC complex could be detected,
whereas the L9Q and F13Y substitutions yielded a subset of
TatBC complexes with apparently increased mass, which may be
indicative of altered subunit composition or significant confor-
mational change. Substrate-induced conformational changes in
the wild-type complex can also be monitored by appearance of a
cross-link between cysteine residues at position 205 at the peri-
plasmic end of TatC transmembrane helix 5. This residue forms
part of the TatB resting-state binding site (50), so is occluded
from dimerization with a neighboring TatC molecule in the
resting state, but has been shown to dimerize in response to
overproduction of a Tat substrate (39). Similarly, assembly of
TatA-YFP oligomers (indicating assembled translocation sites)
that can be monitored by fluorescence microscopy is only seen for
the wild-type translocase upon overproduction of Tat substrates
(34). For one of the TatB substitutions, F13Y, both TatC M205C
dimerization and TatA–YFP assembly were observed not only in
the absence exogenous substrates, but also in the presence of a
TatC F94Q substitution, which disrupts interaction with signal
peptides. We therefore conclude that TatB F13Y has decreased
affinity for the “resting” TatC binding site, and an increased affinity
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Fig. 5. A constitutive disulfide cross-link and aberrant BN-PAGEmigration induced by a subset of TatB suppressors. (A and B) Membranes from E. coli strain DADE
(ΔtatABCD ΔtatE) producing the indicated TatB variants alongside wild-type TatA and TatC from plasmid pTAT1d were solubilized by addition of 2% (wt/vol)
digitonin and analyzed by BN-PAGE (4–16% Bis-Tris NativePAGE gels) followed by Western blot with anti-TatA, anti-TatB, or anti-TatC antibodies as indicated.
Solubilized membranes (20 μg) were loaded in each lane. (C) Membranes from strain DADE producing the indicated TatB variant alongside wild-type TatC from
plasmid pTATBC1d were solubilized and analyzed as inA and B. (D) Whole cells of DADE harboring pTAT101 coproducing either wild-type TatA, the M205C single
cysteine variant of TatC and the indicated substitution in TatB, or wild-type TatA, the TatC F94Q M205C variant of TatC, and the indicated substitution in TatB
were subjected to oxidizing (O) or reducing (R) conditions. Where indicated the additional plasmid pQE80-CueO (producing His-tagged CueO) was also present.
Membranes were prepared from equal quantities of cells following treatment and equivalent amounts of material from each sample were resolved by non-
reducing SDS/PAGE (12% acrylamide). TatC was visualized by Western blotting using an anti-TatC antibody and CueO-His with an anti-His antibody.
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for the “activated” binding site, such that it is able to trigger re-
cruitment of TatA and transport of precursors in the absence of
signal peptide binding. For the other TatB variants, we propose
that each differs in affinity for the resting and activated binding
sites, leading to slight differences in conformation for these
translocases, and we assume that in these cases, weak residual
binding of a signal peptide lacking its twin arginine motif is suffi-
cient to trigger TatA recruitment, whereas in the wild-type system
the higher energy of binding of the twin arginine residues is strictly
required for this. Hence, the signal peptide plays two distinct roles:
in precursor targeting and in translocase activation.
A favored model for Tat-mediated protein translocation is
that protein passage across the membrane is facilitated by bilayer
disruption arising from TatA oligomerization. Interestingly, it
was noted that there was a reduced growth rate associated with
overproduction of Tat systems containing TatB suppressors, in-
cluding F13Y, suggesting apparent toxicity. However, no leak of
the small uncharged sugar, xylitol, could be detected in mem-
branes harboring Tat complexes containing TatB F13Y. This
may suggest the presence of a substrate precursor is necessary to
provide the force required to disrupt the bilayer. Alternatively, it
remains possible that the foci of TatA–YFP observed in cells
producing TatB F13Y do not correspond to fully assembled
translocases and that further recruitment of TatA(–YFP) [for
example mediated by the folded mature domain of a Tat sub-
strate (51)] is required. Indeed the export of mature AmiA in the
presence of the TatB F13Y substitution might suggest that some
Tat substrates have internal targeting information.
In summary, our findings support the notion that Tat signal
peptides have two distinct roles. They serve to target their pas-
senger domains to the export machinery, but also to trigger as-
sembly of the active translocase. The isolation of substitutions in
the Tat machinery that bypass these steps should prove very
useful to dissect the mechanism by which folded protein trans-
location is achieved.
Materials and Methods
Strain Construction. The E. coli strains used in this work are listed in SI Ap-
pendix, Table S3. Strain JM109 was used for regular cloning and trans-
formation of Quickchange products, and ultracompetent cells of XL10-Gold
(Agilent) were used for construction of the random mutagenesis libraries.
Strain DADE [as MC4100, ΔtatABCD, ΔtatE (42)] was used as the back-
ground strain for Tat transport activity tests and production of Tat proteins
for membrane protein extraction, in vivo disulfide cross-linking, and BN-
PAGE, with the exception of Fig. 3, where strain MΔBC [MC4100 ΔtatBC (33)]
was used. Strain DADE-P [as DADE, pcnB1 zad-981::Tn10d (Kanr) (52)] was
used to coproduce TatB and TatC along with AmiA for copurification ex-
periments. Strain MCDSSAC ΔtatABC (37), in which the 2–33 codons of amiA
and 2–32 codons for amiC are deleted and the tatABC operon was replaced
with an apramycin-resistance cassette, was used as the background strain for
AmiA signal sequence library screening and to analyze transport of AmiA
mediated by AmiA or SufI signal peptide variants.
Transport of AmiA mediated by signal sequence truncations was assessed
in strain MC4100 ΔamiA ΔamiC ΔtatABC, which was constructed as follows.
The ΔamiA:kanr allele from the Keio collection (53) was moved into MC4100
by phage P1 transduction, after which the kanamycin-resistance cassette was
eliminated according to Cherepanov and Wackernagel (54). Next, the amiC
deletion was introduced and the kanamycin cassette subsequently elimi-
nated using the same approach. Finally, the ΔtatABC::Apra allele was in-
troduced from strain BW25113 ΔtatABC::Apra (54) by P1 transduction. Strain
BW25113 ΔglpF ΔtatABC was used in osmotic lysis experiments and was
constructed by P1 transduction of the ΔglpF:kanr allele from the Keio col-
lection (53), elimination of the kanamycin resistance, and P1 transduction of
the ΔtatABC::Apra allele, as described above.
Strain AyBCE (34), which lacks tatA at the native locus and has a tatA–YFP
fusion integrated into the chromosomal att site, was used in fluorescence
imaging. Chromosomal point substitutions in tatB and tatC were introduced
into this strain via plasmid pMAK-AupBC and its variants using the approach
of Hamilton et al. (55).
Strain BL21(DE3) ΔtatABC was used to coproduce TatB and TatC along
with SufIss-GFP-His for the copurification experiments. This strain is a de-
rivative of BL21(DE3), where the tatABC genes have been replaced with the
apramycin-resistance cassette, and was constructed by recombination as
described previously (56).
Plasmid Construction. The plasmids used and constructed in this work are
listed in SI Appendix, Table S4. All point mutations in plasmids, as well as
insertion of the flag sequence to create p101C*BCflag, were introduced by
Quickchange site-directed mutagenesis (Stratagene) using the primers listed
in SI Appendix, Table S5.
Plasmids pTAT101 (39) and pTAT1d (38) were used to express tatABC
under the control of the native tatA promoter at very low and medium copy
number, respectively. pTAT101 cys-less (47) was used as the backbone to
introduce single cys substitutions for in vivo disulfide cross-linking experi-
ments. Plasmid pTATBC1d encodes TatBC and was constructed following
amplification of tatBC pTAT1d using primers STIPE-ISH and pT7.5R (SI Ap-
pendix, Table S5) was digested using BamHI and PstI and cloned into simi-
larly digested pUNIPROM (57). Plasmid pBADTatABC-His codes for tatABC
with a hexa His-tag coding sequence at the 3′ end of tatC in pBAD24 (58). It
was constructed following amplification of tatABChis from pUNITAT2 (59),
digestion with NcoI and XbaI and cloning into similarly digested pBAD24.
pSUAmiA (36) was used to produce full-length AmiA from a vector speci-
fying chloramphenicol resistance. pSUSufIss-mAmiA was used to produce
AyBCE
AyBCF94QE AyBCF94QE pSUAmiA
AyBCE pSUAmiA
AyBF13YCE AyBF13YCF94QE
A
B
Fig. 6. The TatB F13Y substitution promotes constitutive oligomerization of
TatA in vivo. (A) Fluorescence images of TatA–YFP in representative cells of
strains AyBCE or AyBCF94QE (encoding the TatC F94Q substitution in chro-
mosomal tatC) in the presence (pSUAmiA) or absence of plasmid-encoded
wild-type AmiA, as indicated. Production of AmiA was induced by addition
of 1 mM IPTG to mid-log cell cultures 45 min before harvesting. (B) Fluo-
rescence images of TatA–YFP in representative cells of strains AyBF13YCE
(encoding the TatB F13Y substitution in chromosomal tatB) and AyBCF94QE
(encoding the TatB F13Y substitution in chromosomal tatB, alongside the
TatC F94Q substitution in chromosomal tatC). (Scale bars, 1 μm.)
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SufIss-mAmiA and was constructed following separate amplification of DNA
encoding the SufI signal sequence, including the sufI ribosome binding site
using primers SufIssFE and SufIssR, and the mature region of AmiA (mAmiA)
using primers AmiA-mF and AmiA-mRX from the chromosome, and fusing
the two fragments by overlap extension PCR according to Heckman and
Pease (60). The resultant DNA fragment was then cloned into the pSU18
vector (61) using EcoRI and XbaI sites to generate pSUSufIss-mAmiA plasmid.
Plasmids pSUSufIssnoH-mAmiA were used for production of truncated
SufIss-mAmiA lacking the signal peptide h-region. It was constructed by
removal of codons 11–21 of the SufI signal sequence via Quickchange using
pSUSufIss-mAmiA as template with primers SufI-noHF and SufI-noHR. pSU-
mAmiA was used to produce signaless AmiA and was constructed as follows.
A DNA fragment containing the ribosome binding site of amiA and the
coding sequence for mature AmiA was amplified using pSUAmiA as tem-
plate with primers AmiA-nossFE and AmiA-mRX. The DNA fragment was
subsequently cloned into pSU18 using EcoRI and XbaI sites to generate
pSUmAmiA. To express the mature domains of AmiA or AmiC from pQE70,
DNA covering these regions were amplified with primer pairs mAmiA-SphI-F/
AmiAnostopBamHI-R or mAmiC-SphI-F/AmiCnostopBamHI-R, respectively,
using chromosomal DNA as a template. The DNA fragments were digested
with SphI and BamHI and cloned into SphI/BglII digested pQE70 vector
(Qiagen). For fractionation experiments, SufI was produced with a C-termi-
nal His-tag from pQE80 (Qiagen). It was cloned by excision of DNA covering
a C-terminally His-tagged SufI from pQE60-SufI (62) as a NheI-XhoI fragment
and ligation into similarly digested pQE80.
Plasmid pMAK-AupBCwas used to introduce themutations into the AyBCE
chromosome and was constructed by amplification of 500 bp of tatA up-
stream DNA from the chromosome of strain AyBCE using primers TatAup1-
XbaI and TatAup2-ClaI, which was cloned into pBluescript KS(+) using XbaI
and ClaI sites to give pKS-Aup. Next, a DNA fragment covering the whole of
tatBC was amplified from the chromosome of AyBCE strain with primers
TatA6B7-ClaI and TatCrev-KpnI, and cloned into pKS-Aup using ClaI and
KpnI sites to generate pKS-AupBC. Subsequently the DNA covering the tatA
upstream sequence along with tatBC was excised using XbaI and KpnI and
cloned into similarly digested pMAK705 (55) to give pMAK-AupBC.
Plasmid pFAT75ΔA-BC, which is a pQE-based plasmid expressing TatB and
TatC without a His-tag (19), and pSufIss-GFP-His, which is a pCDFDuet-based
plasmid expressing synthetic SufI signal sequence-fused GFP with a His-tag at
its C terminus under the control of T7 promoter, were used in copurification
experiments. Plasmid pFAT75ΔA-BC-AmiA-His coproduces untagged TatBC
along with His-tagged AmiA and was constructed as follows. A DNA frag-
ment covering amiA was amplified from MC4100 genomic DNA using pri-
mers AmiAFATApaI-F and AmiAnostopBamHI-R, digested with ApaI and
BamHI and cloned into ApaI/BglII digested pFAT75-SufI-His (47). pFAT75ΔA-
BC-mAmiA-His was constructed similarly, using primer mAmiAFATApaI-F and
AmiAnostopBamHI-R to amply DNA covering the mature region of AmiA.
Mutant Library Construction and Screening. To screen for Tat signal sequence
suppressors, substitutions of the twin arginine sequence of the AmiA signal
peptide (to -RD, -RE, -RN, -RQ, -RH, -HH, -KH. and -KQ) were constructed in the
pSUAmiA plasmid. The resulting plasmids were individually introduced into
strain MCDSSAC ΔtatABC and each resulting strain served as host to screen
an existing tatB mutant library (in plasmid pTAT1d, 600,000 individual
clones, 0.25% error rate) (38).
To screen for suppressors of the TatC F94Q substitution, three separate
mutagenesis libraries, each of which carried the tatC F94Q codon substitution,
were constructed that contained random mutations in either tatAB, codons
1–93 of tatC (tatC1) or codons 95–258 of tatC (tatC2), respectively, using a
modified MEGAWHOP (megaprimer PCR of whole plasmid) method, as described
previously (63). DNA fragments of tatAB, tatC1, and tatC2 containing random
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Fig. 7. No detectable leak of xylitol across the cytoplasmic membrane when cells produce Tat translocases harboring TatB suppressors. (A) Overnight cultures
of E. coli strain BW25113 ΔglpF ΔtatABC harboring pBAD24 encoding TatA and TatC-his along with wild type TatB or each of the L9Q, L10P, F13Y, or I36N
point substitutions, were subcultured at 1:100 dilution into fresh LB medium containing ampicillin, which was supplemented after 120 min with 0.2% of
glucose or arabinose, as indicated. Growth of the strains was followed for a further 6.5 h. Error bars represent SD, n = 3 (biological replicates). (B) The same
strain and plasmid combinations as in A, alongside BW25113 ΔglpF harboring pBAD22SecY(Δplug)EG, were subcultured and supplemented with 0.2% of
arabinose as described in A and grown for an additional 3 h, after which spheroplasts were prepared and incubated in the presence of xylitol. (C) An aliquot
of each sample producing plasmid-encoded Tat proteins was analyzed by SDS/PAGE and Western blotting to confirm expression of TatA, TatB, and TatC-His.
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Fig. 8. Tat translocases containing TatB suppressor variants may more readily
transition to the signal peptide-activated state. (Upper) Model for Tat transport.
A signal peptide bound through its n-region to the cytoplasmic surface of TatC
(step 1) transitions to a deep binding mode (step 2). The deep insertion of the
signal peptide displaces TatB from its resting state binding site on TatC (gray
arrow). TatB movement allows polymerization of TatA to be nucleated (step 3).
The substrate passes across the membrane facilitated by the TatA oligomer (step
4). (Lower) TatB variants that suppress signal sequence defects (represented with
an asterisk, *) may be more easily displaced from the resting-state binding site.
The TatB variants appear to be on a continuum with TatB F13Y pushing the Tat
system into an assembled state (step 4), whereas Tat systems harboring the
weaker suppressing variants are more likely to correspond to step 3.
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mutations were generated using error-prone PCR. Error-prone PCR was carried
out in 1× GoTaq buffer, 7 mMMgCl2, 0.2 mM dATP, 0.2 mM dGTP, 1 mM dCTP,
1 mMdTTP, 0.4 μM each primer, 0–0.1 mMMnCl2, 50 ng pTAT1dCF94Q plasmid
as template, and 5 U GoTaq DNA Polymerase (Promega) in a total volume of
50 μL using a PCR program: 94 °C for 2 min followed by 20 cycles of incubation
at 94 °C for 30 s, 50 °C for 30 s, and 72 °C for 3 min, and a final incubation at
72 °C for 5 min. Primer pairs TatA-FB and TatB-RS were used to amplify tatAB,
TatCm6 and TatC93R to amplify tatC1, and TatC95F and TatCR1d were used to
amplify tatC2. The DNA fragments were then used as megaprimers to amplify
the whole plasmid, which was carried out in a 50-μL mixture containing 1×
Herculase II reaction buffer, 0.5 mM each dNTP, 100 ng pTAT1dCF94Q plasmid
as template, 500 ng DNA fragment obtained above as megaprimers, and 5 U
Herculase II Fusion DNA Polymerase (Agilent) using the PCR program: in-
cubation at 68 °C for 5 min, 95 °C for 2 min, followed by 20 cycles of incubation
at 95 °C for 30 s, 55 °C for 30 s, and 68 °C for 6 min. The resultant whole-plasmid
PCR products were digested with DpnI to remove the template DNA and in-
cubated with T4 polynucleotide kinase and T4 DNA ligase to repair the nicks.
Finally, the whole plasmids were separately transformed into XL10-Gold Ul-
tracompetent Cells (Agilent) resulting in three mutagenesis libraries. Sub-
sequent sequencing of 10 randomly selected colonies from each library
revealed an average error rate of ∼2 nucleotides per 1,000 base pairs. Screening
of these three libraries was carried out in strain DADE (ΔtatABCD, ΔtatE).
For screening experiments, the libraries were transformed into the re-
spective host strains and subsequently plated onto solid LBmedium containing
appropriate antibiotics and 2% (wt/vol) SDS for selection. Colonies able to
grow under these conditions were isolated, the mutations in the tat genes
identified by sequencing and retested for growth in the presence and ab-
sence of 2% (wt/vol) SDS. To further verify isolated candidates, individual
mutations were introduced into low copy number plasmid pTAT101 by site-
directed mutagenesis and the activity was again assessed on 2% (wt/vol) SDS-
containing plates.
Protein Methods. For copurification of TatBC-substrate complexes, cultures of
strain BL21(DE3) ΔtatABC harboring pFAT75ΔA (or a point-substituted variant)
and pSufI-GFP-His were incubated at 37 °C for 7 h with shaking, after which
they were supplemented with 0.2 mM isopropyl β-D-1-thiogalactopyranoside
(IPTG) and incubated for an additional 17 h at 37 °C. The cells were sub-
sequently harvested and resuspended in 1× PBS, the fluorescence intensity of
the suspension was recorded, after which the cells were repelleted, resus-
pended in 2× lysis buffer (100 mM NaH2PO4 pH 8.0, 600 mM NaCl, 40 mM
imidazole, 50 mg lysozyme, 80 U benzonase, and protease inhibitor) and
mixed gently at room temperature for 1 h. Cells were snap-frozen at −80 °C,
thawed at room temperature, and an equivalent amount of 2.5% (wt/vol)
digitonin was added and the sample gently mixed at room temperature for
1 h. Cell debris was pelleted by centrifugation and the supernatant was
transferred to a 96-well plate and mixed with 20 μL Ni-NTA Magnetic Agarose
Beads (Qiagen) for 1 h. After the beads were washed three times with wash
buffer (50 mM NaH2PO4, pH 8.0, 300 mM NaCl, 40 mM imidazole, 0.03%
digitonin), bound proteins were eluted with 50 μL elution buffer (50 mM
NaH2PO4, pH 8.0, 300 mM NaCl, 250 mM imidazole, 0.03% digitonin).
In vivo disulfide cross-linking was carried out in strain DADE harboring
pTAT101 cys-less CM205C, as described in Cléon et al. (47). BN-PAGE was
undertaken according to refs. 47 and 64. Subcellular fractionation was
according to Palmer et al. (65). Preparation of membrane fractions was as
described previously (39). For analysis of SufI export, E. coli strain DADE
harboring wild-type or signal peptide variants of pQE80SufI-His alone or
alongside wild-type or TatB variants of pTAT101 was cultured in the pres-
ence of 1 mM IPTG until OD600 of 1 was reached. Samples (equivalent to 150 μL
of whole cells from an OD600 = 1, or periplasm fractions from the equiva-
lent of 300 μL of cells from an OD600 = 1) were separated by SDS/PAGE and
analyzed by Western blot with anti-6× His-tag or anti-RNA polymerase
β-subunit antibodies (cytoplasmic control protein). For analysis of CueO ex-
port, strain MΔBC harboring wild-type and KK variants of pQE80-CueO
alongside wild-type, tatBE8K or tatBF13Y variants of p101C*BCflag were cul-
tured and fractionated as previously described (34). Immunoblotting was
according to the methodology of Towbin et al. (66), and antibodies to TatA,
TatB, and TatC have been described previously (47, 67). Anti-6× His-tag anti-
body (HRP-conjugated) was purchased from Abcam (catalog no. ab184607),
anti-DnaK mouse monoclonal 8E2/2 antibody was also from Abcam (catalog
no. ab69617), and a mouse monoclonal anti-RNA polymerase β-subunit anti-
body was purchased from NeoClone Biotechnology (catalog no. W0023).
Secondary antibodies were goat anti-Rabbit IgG (HRP Conjugate, catalog no.
170-6515) or Goat Anti-Mouse IgG (HRP conjugate, catalog no.170-6516),
both from Bio-Rad. Immunoreactive bands were visualized with the Clarity
Western ECL Substrate Kit (Bio-Rad) and captured either on light-sensitive film
or using the GeneGNOME camera (Syngene).
Cell Permeability Experiments. Cell permeability experiments were performed
according to Park and Rapoport (48). Briefly, cells were grown aerobically at 37 °C
with 1:100 inoculation of an overnight culture for 2 h. Production of TatABC
harboring TatB variants and of SecY(Δplug)EG was induced by addition of 0.2%
arabinose at 37 °C for 3 h. Subsequently, the OD600nm of each sample was nor-
malized using LB, a small volume was withdrawn for Western blotting, and equal
volumes of each culture were then harvested and resuspended in fractionation
buffer (50 mM Tris·HCl buffer, 20% (wt/vol) sucrose, pH 7.5, 5 mM EDTA, 0.6 mg/mL
lysozyme) and incubated at room temperature for 20 min to obtain sphero-
plasts. The spheroplast samples were then adjusted to the same OD600 and a
19-fold excess of 0.616 M xylitol solution was added. The samples were rapidly
transferred to a 96-well plate and OD600 was measured every 30 s for 300 s.
Fluorescence Microscopy. Cells were prepared for fluorescence microscopy
and imaged as previously described (47), with the exception that a 550-nm LP
emission filter was used.
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